Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets.
advances
antiangiogenics
castration-resistant prostate cancer
hormone-sensitive prostate cancer
prostate cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
14 Sep 2021
14 Sep 2021
Historique:
received:
19
08
2021
revised:
06
09
2021
accepted:
13
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
25
2
2023
Statut:
epublish
Résumé
Prostate cancer (PC) is the most common cancer in men and the second leading cause of cancer-related death worldwide. Many therapeutic advances over the last two decades have led to an improvement in the survival of patients with metastatic PC, yet the majority of these patients still succumb to their disease. Antiagiogenic therapies have shown substantial benefits for many types of cancer but only a marginal benefit for PC. Ongoing clinical trials investigate antiangiogenic monotherapies or combination therapies. Despite the important role of angiogenesis in PC, clinical trials in refractory castration-resistant PC (CRPC) have demonstrated increased toxicity with no clinical benefit. A better understanding of the mechanism of angiogenesis may help to understand the failure of trials, possibly leading to the development of new targeted anti-angiogenic therapies in PC. These could include the identification of specific subsets of patients who might benefit from these therapeutic strategies. This paper provides a comprehensive review of the pathways involved in the angiogenesis, the chemotherapeutic agents with antiangiogenic activity, the available studies on anti-angiogenic agents and the potential mechanisms of resistance.
Identifiants
pubmed: 34576107
pii: ijms22189926
doi: 10.3390/ijms22189926
pmc: PMC8472415
pii:
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Antineoplastic Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Invest New Drugs. 2014 Aug;32(4):746-52
pubmed: 24671507
Clin Cancer Res. 2011 Apr 15;17(8):2281-91
pubmed: 21220477
N Engl J Med. 2013 Jan 10;368(2):138-48
pubmed: 23228172
Asian Pac J Cancer Prev. 2015;16(9):3969-72
pubmed: 25987070
Eur J Cancer Prev. 2010 Sep;19(5):385-92
pubmed: 20502342
Endocr Metab Immune Disord Drug Targets. 2006 Mar;6(1):17-24
pubmed: 16611161
Lancet Oncol. 2015 Apr;16(4):417-25
pubmed: 25743937
BJU Int. 2007 May;99(5):1047-55
pubmed: 17437439
Clin Cancer Res. 2005 Nov 1;11(21):7658-63
pubmed: 16278385
Nat Rev Urol. 2013 Apr;10(4):187
pubmed: 23459034
Clin Cancer Res. 2001 Jul;7(7):1888-93
pubmed: 11448901
Ann Gastroenterol. 2017;30(6):613-621
pubmed: 29118555
Technol Cancer Res Treat. 2021 Jan-Dec;20:1533033821990010
pubmed: 33752529
Cancer. 2016 Jul 1;122(13):2004-11
pubmed: 27028170
Ann Gastroenterol. 2018 Nov-Dec;31(6):659-669
pubmed: 30386115
Biomedicines. 2020 Nov 16;8(11):
pubmed: 33207809
Cancer Lett. 2003 Mar 10;191(2):125-35
pubmed: 12618325
J Gene Med. 2018 May;20(5):e3016
pubmed: 29578262
Anticancer Agents Med Chem. 2009 Jan;9(1):66-76
pubmed: 19149483
Lancet Oncol. 2013 Jul;14(8):760-8
pubmed: 23742877
Semin Cancer Biol. 2019 Jun;56:100-115
pubmed: 29155240
Clin Chim Acta. 2015 Dec 7;451(Pt B):154-60
pubmed: 26415820
Prostate. 2005 Feb 1;62(2):115-22
pubmed: 15389797
Cancer Chemother Pharmacol. 1999;43 Suppl:S78-84
pubmed: 10357564
Oncogene. 2018 Aug;37(34):4735-4749
pubmed: 29765153
Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5
pubmed: 7513432
Cancer Discov. 2017 Jul;7(7):750-765
pubmed: 28274958
Mol Carcinog. 2020 Mar;59(3):323-332
pubmed: 31943365
Genes (Basel). 2020 Nov 25;11(12):
pubmed: 33255593
Semin Oncol. 1999 Oct;26(5 Suppl 17):3-7
pubmed: 10604261
J Clin Oncol. 2014 Dec 20;32(36):4066-72
pubmed: 25385735
Nat Rev Mol Cell Biol. 2006 May;7(5):359-71
pubmed: 16633338
Urology. 2007 Mar;69(3):526-31
pubmed: 17382158
Eur J Cancer. 2018 May;94:115-125
pubmed: 29550566
Oncogene. 2017 Feb 2;36(5):687-699
pubmed: 27375020
J Pers Med. 2019 Feb 07;9(1):
pubmed: 30736475
Prostate Cancer. 2013;2013:418340
pubmed: 24396604
Diagnostics (Basel). 2020 Jul 31;10(8):
pubmed: 32752137
J Biol Chem. 2006 Jan 13;281(2):951-61
pubmed: 16278208
Methods Mol Biol. 2018;1856:103-117
pubmed: 30178248
Front Cell Dev Biol. 2020 Jul 08;8:605
pubmed: 32733895
Nat Cell Biol. 2021 Jan;23(1):3-5
pubmed: 33420486
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
Urol Oncol. 2013 Nov;31(8):1567-75
pubmed: 22608542
Methods Mol Biol. 2018;1786:153-173
pubmed: 29786792
Clin Transl Oncol. 2020 Jan;22(1):111-121
pubmed: 31667686
Br J Cancer. 2001 Aug 17;85(4):576-83
pubmed: 11506499
Clin Cancer Res. 2017 Oct 15;23(20):6062-6069
pubmed: 28751444
Br J Cancer. 2009 Oct 20;101(8):1233-40
pubmed: 19755981
Eur Urol. 2019 Jun;75(6):929-937
pubmed: 30528222
J Clin Oncol. 1996 May;14(5):1617-25
pubmed: 8622080
Mol Cell Endocrinol. 2018 Feb 15;462(Pt A):25-30
pubmed: 28315704
Prostate. 2017 Jan;77(1):72-81
pubmed: 27604827
Nat Rev Cancer. 2008 Aug;8(8):592-603
pubmed: 18650835
Prostate. 2007 May 15;67(7):790-7
pubmed: 17373719
Eur Urol. 2012 Sep;62(3):418-30
pubmed: 22749850
N Engl J Med. 2019 Jul 4;381(1):13-24
pubmed: 31150574
BJU Int. 2006 Oct;98(4):763-9
pubmed: 16796694
Int J Mol Sci. 2019 May 31;20(11):
pubmed: 31151317
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Semin Oncol. 2000 Apr;27(2 Suppl 3):24-9
pubmed: 10810935
Front Oncol. 2020 May 19;10:725
pubmed: 32509575
Laryngoscope. 2012 Apr;122(4):839-43
pubmed: 22374860
Br J Cancer. 2007 Dec 3;97(11):1480-5
pubmed: 18040273
Urology. 1999 Sep;54(3):523-7
pubmed: 10475365
Clin Cancer Res. 2008 Jan 1;14(1):209-14
pubmed: 18172272
BJU Int. 2020 Jan;125(1):89-102
pubmed: 31392791
J Clin Oncol. 2010 Apr 20;28(12):2070-6
pubmed: 20308663
Ann Oncol. 2008 Apr;19(4):746-51
pubmed: 18056648
Cancer Biother Radiopharm. 2009 Apr;24(2):175-80
pubmed: 19409038
N Engl J Med. 2017 Jul 27;377(4):338-351
pubmed: 28578639
Clin Genitourin Cancer. 2019 Feb;17(1):e92-e96
pubmed: 30327180
Oral Oncol. 2011 Jun;47(6):459-66
pubmed: 21530364
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Nat Rev Urol. 2017 Jun;14(6):327
pubmed: 28352136
Ann Oncol. 2009 May;20(5):913-20
pubmed: 19403935
Neoplasia. 2010 Jun;12(6):464-75
pubmed: 20563249
Semin Oncol. 2001 Aug;28(4 Suppl 15):62-6
pubmed: 11685731
Prostate Cancer Prostatic Dis. 2002;5(2):123-7
pubmed: 12497001
Cancer Lett. 2004 Nov 8;215(1):1-20
pubmed: 15374627
Oncologist. 2013;18(2):163-73
pubmed: 23340005
Cancer Res. 2004 Aug 1;64(15):5311-21
pubmed: 15289337
Cancer Med. 2017 Oct;6(10):2461-2470
pubmed: 28941222
J Clin Oncol. 2012 May 1;30(13):1534-40
pubmed: 22454414
Mol Ther. 2018 Jul 5;26(7):1855-1866
pubmed: 29807781
J Oncol. 2010;2010:361836
pubmed: 20169138
Ecancermedicalscience. 2015 Apr 15;9:521
pubmed: 25932045
Asian J Androl. 2014 May-Jun;16(3):372-7
pubmed: 24759579
Am J Surg Pathol. 2016 Feb;40(2):244-52
pubmed: 26492179
Eur Urol. 2016 Jan;69(1):107-15
pubmed: 25481455
J Tissue Eng. 2010 Nov 07;2010:218142
pubmed: 21350642
J Clin Oncol. 2011 Oct 20;29(30):4022-8
pubmed: 21931019
J Formos Med Assoc. 2020 Jul;119(7):1201-1210
pubmed: 31718853
J Urol. 2013 Aug;190(2):496-501
pubmed: 23466239
Prostate. 2004 Feb 1;58(2):193-9
pubmed: 14716745
Int J Mol Sci. 2020 Feb 18;21(4):
pubmed: 32085654
Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5223-5232
pubmed: 30819896
Prostate. 2005 Oct 1;65(2):110-6
pubmed: 15880525
Eur Urol. 2012 Sep;62(3):405-17
pubmed: 22749852
Int J Biochem Cell Biol. 2018 Sep;102:109-116
pubmed: 30010013
Biomaterials. 1996 Jan;17(2):155-62
pubmed: 8624392
Cancer Res. 2007 Jun 15;67(12):5789-97
pubmed: 17575146
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8
pubmed: 12177445
Eur Urol. 2016 Mar;69(3):428-35
pubmed: 26166626
Expert Opin Ther Targets. 2021 May;25(5):329-333
pubmed: 34225539
Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):737-44
pubmed: 25752386
Cancer. 2011 Feb 1;117(3):526-33
pubmed: 20862750
Cancer Cell. 2015 Jun 8;27(6):809-21
pubmed: 25982816
Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1537-49
pubmed: 12459383
Microsc Res Tech. 2001 Feb 15;52(4):411-9
pubmed: 11170300
CA Cancer J Clin. 2015 Jul-Aug;65(4):265-82
pubmed: 25958817
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
Can J Urol. 2007 Oct;14(5):3669-77
pubmed: 17949520
Lancet Oncol. 2016 Jul;17(7):917-927
pubmed: 27279544
Clin Cancer Res. 2009 Oct 1;15(19):6277-83
pubmed: 19773375
Clin Transl Oncol. 2019 Feb;21(2):126-144
pubmed: 29951892
Diagnostics (Basel). 2021 Jul 26;11(8):
pubmed: 34441278
JAMA Oncol. 2017 Oct 1;3(10):1415-1422
pubmed: 28097325
Clin Transl Oncol. 2016 Oct;18(10):972-80
pubmed: 26856599
Nat Rev Cancer. 2003 Jun;3(6):401-10
pubmed: 12778130
Oncogene. 2010 Feb 4;29(5):625-34
pubmed: 19946328
Acta Clin Croat. 2019 Mar;58(1):128-138
pubmed: 31363335
J Clin Oncol. 2004 Jul 1;22(13):2532-9
pubmed: 15226321
Eur Urol. 2008 Nov;54(5):1089-94
pubmed: 18276061
Cancer Lett. 2019 Apr 28;448:1-10
pubmed: 30673592
Eur Urol. 2017 Aug;72(2):177-188
pubmed: 28196723
Int J Urol. 2008 Aug;15(8):754
pubmed: 18786200
Int J Mol Sci. 2018 Jul 12;19(7):
pubmed: 30002349
Br J Cancer. 1996 Sep;74(6):910-6
pubmed: 8826857
N Engl J Med. 2017 Jul 27;377(4):352-360
pubmed: 28578607
Acta Orthop Scand Suppl. 1996 Apr;269:1-33
pubmed: 8629452
Gen Pharmacol. 1998 Nov;31(5):759-64
pubmed: 9809475
Eur Urol. 2016 Aug;70(2):312-22
pubmed: 26806656
Cancer Lett. 2017 Oct 28;407:9-20
pubmed: 28823964
Br J Cancer. 2010 Mar 2;102(5):922-9
pubmed: 20160732
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566
Br J Cancer. 2010 Aug 24;103(5):708-14
pubmed: 20664589
J Urol. 2005 Jan;173(1):10-20
pubmed: 15592017
Bull Cancer. 2017 May;104(5):393-401
pubmed: 28477875
BJU Int. 2014 Jun;113(6):986-92
pubmed: 24053309
J Natl Compr Canc Netw. 2016 Jan;14(1):19-30
pubmed: 26733552
Lancet Oncol. 2021 Aug;22(8):1126-1138
pubmed: 34237250
J Pers Med. 2020 May 21;10(2):
pubmed: 32455595
Genes Dev. 2008 May 15;22(10):1276-312
pubmed: 18483217
Am J Pathol. 1999 Oct;155(4):1271-9
pubmed: 10514409